about
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humansManagement of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.The origins of pandemic influenza--lessons from the 1918 virus.Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinationsSafety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.The herpevac trial for women: Sequence analysis of glycoproteins from viruses obtained from infected subjects.Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection.A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infectionSafety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjectsDNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial.Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination.Current status of live attenuated influenza virus vaccine in the US.Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccineHigher Throughput Quantification of Neutralizing Antibody to Herpes Simplex Viruses.Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults.Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age.Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.Genomic analysis of vaccine-derived poliovirus strains in stool specimens by combination of full-length PCR and oligonucleotide microarray hybridization.A systematic review of the efficacy of live attenuated influenza vaccine upon revaccination of children.Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection.Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity.Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children.Genetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine.Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.The immunogenetics of smallpox vaccination.Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in AdultsDevelopment of a high-throughput β-Gal-based neutralization assay for quantitation of herpes simplex virus-neutralizing antibodies in human samples.Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.Molecular evolution of herpes simplex virus 2 complete genomes: Comparison between primary and recurrent infections.Comparison of results of detection of rhinovirus by PCR and viral culture in human nasal wash specimens from subjects with and without clinical symptoms of respiratory illness.The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination.Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.
P50
Q28488268-10BC74DE-EF36-4008-96B8-0D2E62B74B52Q30312048-6A896543-3D7F-4CB5-B8A3-11D244F736A4Q30351929-D48EE3C2-3AA6-4ADB-AF27-EF7B26454956Q30369098-32A7F647-B0A9-4C38-837F-818B23544FA3Q30372087-A6C497C7-EAE9-4341-99C3-939629BF7761Q30390832-5D9281B4-59EA-416A-91EF-E64CE59CB1D8Q33610941-EF607B77-C212-4DC5-8B47-D633445D7BE3Q33927681-DD6989D9-48D3-4C6F-98B1-1F595986A210Q34009510-1AA35DEB-5372-4441-B233-C9416996DBD4Q34072573-28D2CE25-C6BC-42E3-BD5C-0B684AECEE4DQ34097560-11583247-CA8D-4E9A-8B49-F85944BEF5C6Q34594986-14591901-1276-4B7D-9CF0-992974ED842CQ34697810-88B60C44-4405-4CC9-AAB1-5F732571742AQ35581929-B14E6A37-A380-4C1E-8E77-9D93092FA9DCQ35688299-5E27C83F-249C-442D-8813-D6DD58856413Q35784263-83C3A8D4-9ABA-480E-BC01-D2B735D7CF9EQ35866636-DCC988A7-02EB-4DE7-8679-00C120CC1149Q35866976-9F752DA9-4AB4-4EBD-B81B-65ED10025B5BQ36289253-9EE70A1E-D927-4FE3-80E1-98D4C3C2B3D0Q37087100-7E999E91-3C83-49B5-8231-4DFF8C16D994Q37269295-DB7D3320-3EE7-4F67-A8F4-0CED018B2BB4Q37384009-3233E665-BBA5-4DFC-9190-FDA5C623834AQ38059737-C539D970-907C-4A97-9BA4-BC7F3487C941Q38392346-EEC3CE0F-5E5E-45BA-8844-B7832C3585DDQ38422597-797A7897-922C-44C0-9CE7-0C8495381C35Q38442337-56070E22-C371-4EA0-85B6-68B73B8CCC9DQ38692107-29351866-146C-4219-A7D0-E73777BF4B53Q39029460-D022E4B6-906F-4FE6-93BC-01BD2269DBD4Q40196429-1CF98144-A227-475E-8DB5-BB54B0CB7EF1Q40291541-2659CB0E-8AAE-4164-B550-CDB28403A946Q40358535-E2A57447-AAFA-4B5E-B690-02EF10543EA1Q40414736-E57A48E7-25EA-40E6-8E65-8897572E906AQ40447133-8C09EA60-8A9D-4C5F-918F-13A701F52CD4Q40450539-E386624B-6838-4490-B0E3-986EF0BEA5B2Q40717625-EE038FE7-D1CF-4826-A009-1BAAD71DD476Q41122192-D6975A02-4BCE-4AD9-AFAA-62C92CB01F3FQ41933426-8BACDE24-4814-4F36-B75D-2A13EBA5CC61Q42432272-F7D44BE5-89D4-461F-85BC-A4C2C1A57DC4Q44311458-F371DA04-5414-4799-8789-4153D3FFD649Q45420926-00FC0E12-86D8-4C58-86F6-8BFD41129E13
P50
description
researcher
@en
name
Robert B Belshe
@en
type
label
Robert B Belshe
@en
prefLabel
Robert B Belshe
@en
P31
P496
0000-0003-0940-7213